Alzheimer Agitation Therapy Brexpiprazole Maintains Safe Profile in Longitudinal Analysis

Over a 24-week period, comprising both the core study and extension trial, the incidence of treatment-emergent adverse events was infrequent, with less occurring over the long-term extension.:

Source: Neurology Read More